Matthew E.J. Callister
Leeds Teaching Hospitals NHS Trust
CancerInternal medicineRadiologySurgeryRandomized controlled trialIntensive care medicineStage (cooking)SABR volatility modelLung cancerLung cancer screeningLungNodule (medicine)DiseaseMalignancyMEDLINEPopulationCt screeningIn patientRadiation therapyGeneral surgeryMedicine
Publications 90
#1Stephen H Bradley (University of Leeds)H-Index: 6
#2Bobby Bhartia (Leeds Teaching Hospitals NHS Trust)H-Index: 3
Last. Richard D Neal (University of Leeds)H-Index: 52
view all 10 authors...
BACKGROUND Chest x-ray (CXR) is the first line investigation for lung cancer in many healthcare systems. Understanding of the consequences of false negative CXRs on time to diagnosis, stage and survival is limited. AIMS To determine the sensitivity of CXR for lung cancer and to compare stage at diagnosis, time to diagnosis and survival between those with CXR which detected, or did not detect, lung cancer. DESIGN & SETTING Retrospective observational study using routinely collected healthcare dat...
#1Hilary A. Robbins (IARC: International Agency for Research on Cancer)H-Index: 13
#2Karine Alcala (IARC: International Agency for Research on Cancer)H-Index: 2
Last. Mattias Johansson (IARC: International Agency for Research on Cancer)H-Index: 59
view all 11 authors...
Background The National Health Service England (NHS) classifies individuals as eligible for lung cancer screening using two risk prediction models, PLCOm2012 and Liverpool Lung Project-v2 (LLPv2). However, no study has compared the performance of lung cancer risk models in the UK. Methods We analysed current and former smokers aged 40-80 years in the UK Biobank (N = 217,199), EPIC-UK (N = 30,813), and Generations Study (N = 25,777). We quantified model calibration (ratio of expected to observed ...
#1Stephen H Bradley (University of Leeds)H-Index: 6
#2Nathaniel Luke Fielding Hatton (Leeds Teaching Hospitals NHS Trust)
Last. Richard D Neal (University of Leeds)H-Index: 52
view all 10 authors...
Background Chest X-ray (CXR) is the first-line investigation for lung cancer in many countries but previous research has suggested that the disease is not detected by CXR in approximately 20% of patients. The risk of lung cancer, with particular symptoms, following a negative CXR is not known. Aim To establish the sensitivity and specificity of CXR requested by patients who are symptomatic; determine the positive predictive values (PPVs) of each presenting symptom of lung cancer following a nega...
#1Hilary A. RobbinsH-Index: 13
#2Karine AlcalaH-Index: 2
Last. M. Johansson (IARC: International Agency for Research on Cancer)H-Index: 7
view all 13 authors...
#1Emily C. Bartlett (NIH: National Institutes of Health)
#2Mario Silva (University of Parma)H-Index: 17
Last. Anand Devaraj (NIH: National Institutes of Health)H-Index: 33
view all 4 authors...
Identifying false negative cases is an important quality metric in lung cancer screening but these have been infrequently and variably reported in previous studies. Although as a proportion of all screening participants, false negative cases are uncommon, such cases may constitute a significant proportion of all lung cancers diagnosed (up to 15%) within a screening programme. This article reviews the impact and causes of false negative lung cancer screening tests, including those related to radi...
#1David R Baldwin (University of Nottingham)H-Index: 43
#2Matthew E.J. Callister (St James's University Hospital)H-Index: 18
Last. Robert Steele (Dund.: University of Dundee)H-Index: 81
view all 7 authors...
Use of biomarkers to select participants for lung cancer CT screening could improve clinical and cost effectiveness. It is crucial to design research that evaluates biomarkers against LDCT and to test them in the population in which they will be used.
#1Matthew E.J. Callister (St James's University Hospital)H-Index: 18
#2Peter Sasieni ('KCL': King's College London)H-Index: 77
Last. Hilary A. Robbins (IARC: International Agency for Research on Cancer)H-Index: 13
view all 3 authors...
#1Philip Crosbie (University of Manchester)H-Index: 14
#2Rhian Gabe (QMUL: Queen Mary University of London)H-Index: 24
Last. Matthew E.J. Callister (Leeds Teaching Hospitals NHS Trust)H-Index: 18
view all 23 authors...
Introduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial. Here, we present the Yorkshire Lung Screening Trial (YLST), which will address key questions of relevance for screening implementation. Methods and analysis Using a single-consent Zelen’s design, ever-smokers aged 55–80 years registered with a general practice in Leeds will be randomised (1:1) to invitat...
6 CitationsSource
#1Rachael L Murray (University of Nottingham)H-Index: 18
Last. Matthew E.J. CallisterH-Index: 18
view all 16 authors...
Introduction:Integration of smoking cessation (SC) into lung cancer screening (LCS) is essential to optimise clinical and cost effectiveness. The most effective way to use this “teachable moment” is unclear. The Yorkshire Enhanced Stop Smoking study (YESS) will measure the effectiveness of a SC service integrated within the Yorkshire Lung Screening Trial (YLST) and will test the efficacy of a personalised SC intervention, incorporating incidental findings detected on the low-dose computed tomogr...
4 CitationsSource
Screening for lung cancer with low radiation dose CT has been shown to be effective in reducing lung cancer mortality by two major randomised controlled trials. Lung cancer screening is set to become the largest targeted cancer screening programme globally, but the effectiveness of the programme is dependent on many different factors. This article describes the key evidence for lung cancer screening, the key factors important for optimisation and the progress towards implementation.